+91 861 899 5355

Dr. Daniel Acosta



14 years of experience





Medical Oncology

Procedures Performed

Immunotherapy, Chemotherapy, Targeted Therapy

Work Experience

Medical Oncologist

Vall d’Hebron University Hospital

Barcelona, Spain.

from 2019

Medical Oncologist


Madrid, Spain.

2016 - 2019

Medical Oncologist

Comprehensive Cancer Center CLARA CAMPAL

Madrid, Spain.

2014 - 2016

Medical Oncology Residency Program

San Carlos Clinical Hospital

Madrid, Spain.

2009 - 2014


MD, University of San Martin de Porres



Dr. Acosta is a medical oncologist with extensive experience in treating digestive tumors, including pancreas, biliary tract, liver, esophageal, gastric, colon, and neuroendocrine tumors. He completed his Medical Oncology Residency Program at San Carlos Clinical Hospital in Madrid, Spain, in 2014 and holds an MD from the University of San Martin de Porres.

Dr. Acosta has worked at several medical institutions in Spain, including GenesisCare in Madrid from 2016 to 2019, and the Comprehensive Cancer Center CLARA CAMPAL from 2014 to 2016. He is currently a medical oncologist and clinical researcher in the Digestive and Endocrine Tumors Unit of Vall d´Hebron Institute of Oncology (VHIO).

In addition to his clinical work, Dr. Acosta is actively involved in various national and international organizations dedicated to medical oncology, including the Spanish Society of Medical Oncology, the European Society for Medical Oncology, American Society of Clinical Oncology, The European Neuroendocrine Tumor Society, and Spanish Group of Neuroendocrine and Endocrine Tumors.

Dr. Acosta's areas of expertise include chemotherapy, immunotherapy, and targeted therapies. He is also experienced in drug development and clinical research.


Spanish Society of Medical Oncology

European Society for Medical Oncology

American Society of Clinical Oncology

The European Neuroendocrine Tumor Society

Spanish Group of Neuroendocrine and Endocrine Tumors


Experience with eribulin in patients with metastatic breast cancer and associated hepatic impairment: Case studies

Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital PCR. cfDNA a powerful tool for biomarker testing in advance disease

Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging

Book Medical Expert for Consultation

Daniel Acosta


Fill out the form below to book a consultation with the chosen Medical Expert.
We will contact you for further steps.

Thank you!

We got your request. Our experts will contact you for further steps.